Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Stock analysts at Lifesci Capital boosted their Q3 2024 EPS estimates for shares of Enliven Therapeutics in a research note issued on Wednesday, August 14th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($0.55) for the quarter, up from their prior estimate of ($0.56). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($2.26) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q4 2024 earnings at ($0.57) EPS, FY2024 earnings at ($2.08) EPS and FY2025 earnings at ($2.64) EPS.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.17.
Read Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Stock Performance
Shares of ELVN stock opened at $23.71 on Friday. Enliven Therapeutics has a fifty-two week low of $9.80 and a fifty-two week high of $27.67. The stock’s fifty day moving average is $22.90 and its two-hundred day moving average is $20.12. The firm has a market capitalization of $1.12 billion, a P/E ratio of -12.28 and a beta of 1.10.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC lifted its position in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after buying an additional 305,397 shares during the last quarter. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics in the 2nd quarter worth approximately $9,657,000. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $4,489,000. Baker BROS. Advisors LP acquired a new stake in Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Finally, Bank of New York Mellon Corp raised its position in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after purchasing an additional 37,632 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard A. Heyman sold 1,270 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $24.80, for a total value of $31,496.00. Following the completion of the transaction, the director now owns 133,345 shares in the company, valued at $3,306,956. The disclosure for this sale can be found here. Insiders sold 123,668 shares of company stock valued at $3,057,633 in the last three months. 29.20% of the stock is currently owned by insiders.
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 8/12 – 8/16
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.